MedTrace Logo

Echinacea Drug for Covid-19

NCT04981314 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2021-08-10

No results posted yet for this study

Summary

The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA, hard caplets containing cryogenized root of the plant Echinacea purpurea, show an improvement of the clinical manifestations and disease course in ambulatory patients with covid-19 with a respiratory presentation and not requiring hospitalization (i.e., mild covid-19). The drug being evaluated will be added as a supplement of the standard treatment, with its current recommended dose for treatment of the common cold. 2) Safety: to determine that the incidence of adverse events is not higher than that seen with the standard treatment applied in each case.

Conditions

  • Covid19

Interventions

DRUG

Equinacea Arkopharma

Echinacea hard caplets

OTHER

Placebo

Placebo hard caplets

Sponsors & Collaborators

  • IDIS

    collaborator UNKNOWN

  • SALUD

    collaborator UNKNOWN

  • Laboratoires Arkopharma

    collaborator INDUSTRY

  • Jesús R. Requena

    lead OTHER

Principal Investigators

  • José Luis Pérez-Albiac · SALUD (Servicio Aragonés de Salud), Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-18
Primary Completion
2021-10-01
Completion
2021-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04981314 on ClinicalTrials.gov